Potent T cell modulating molecules

Details Potent T cell modulating molecules Potent T cell modulating molecules

2003-10-10

2010-10-26

Skelding, Zachary (Department: 1644)

Drug, bio-affecting and body treating compositions

Immunoglobulin, antiserum, antibody, or antibody fragment,...

Monoclonal antibody or fragment thereof

C424S154100, C424S156100

Reexamination Certificate

active

07820166

ABSTRACT:
The present invention relates to a polypeptide construct comprising at least one CDR3 region, wherein at least one of the at least CDR3 regions comprises at least one substitution in the amino acid sequence YYDDHY (SEQ ID NO.1) and wherein the at least one substitution comprises: in the first position of SEQ ID NO.1 a substitution from Y to H; in the second position of SEQ ID NO. 1 a substitution from Y to S, from Y to N, from Y to F or from Y to H; in third position of SEQ ID NO. 1 a substitution from D to N or from D to E; in the forth position of SEQ ID NO. 1 a substitution from D to Q, from D to A, from D to V, from D to E or from D to G; in the fifth position of SEQ ID NO. 1 a substitution from H to Q, from H to P, from H to Y, from H to R or from H to N; or in the sixth position a substitution from Y to N.

REFERENCES:
patent: 5859205 (1999-01-01), Adair et al.
patent: 6352694 (2002-03-01), June et al.
patent: WO 99/54440 (1999-10-01), None
Bortoletto et al., Eur. J. Immunol. 2002. 32: 3102-3107, published online Oct. 16, 2002.by Wiley InterSceince/Eur. J. Immunol.
Bortoletto et al., Eur. J. Immunol. 2002. 32: 3102-3107, published as a hard copy in the Nov. 2002 issue of the Eur. J. Immunol.
Janeway et al., Immunobiology, 5th Ed., Garland Science, pp. 94-105 (2001).
Vajdos et al., J Mol Biol. Jul. 5, 2002;320(2):415-28.
Rudikoff et al, Proc. Natl. Acad. Sci. USA, 79: 1979-1 983, Mar. 1982.
Chien et al., Proc Natl Acad Sci U S A. Jul. 1989;86(14):5532-6.
Alegre et al., J Immunol. Feb. 15, 1991;146(4):1184-91.
Woodle et al., Transplantation. Sep. 15, 1999;68(5):608-16.
Colman P. M., Research in Immunology, 145:33-36, 1994.
Chatenoud et al., Curr Opin Immunol. Dec. 2005;17(6):632-7.
Schlereth et al., Cancer Immunol Immunother. May 2006;55(5):503-14.
Portolano et al., J Immunol. Feb. 1, 1993;150(3):880-7.
Eduardo Padlan, Mol Immunol. Feb. 1994;31(3):169-217.
Presentation entitled “Enablement Issues in the Examination of Antibodies,” presented to the BCP Customer Partnership, Jun. 13, 2007.
Presentation of Bennett Celsa (Quality Assurance Specialist, TC 1600) entitled “Written Description: Antibodies” presented to the BCP Customer Partnership, Jun. 2, 2009.
Bachmann et al., “The role of T-cell receptor dimerization in T-cell activation,”Immunology Today, Dec. 1999, pp. 568-575, vol. 20, No. 12.
Baker et al., “αβ T Cell Receptor Ligan-Specific Oligomerization Revisited,”ImmunityJun. 2001, pp. 681-693, vol. 14, Cell Press.
Brühl et al., “Depletion of CCR5-Expressing Cells with Bispecific Antibodies and Chemokine Toxins: A New Strategy in the Treatment of Chronic Inflammatory Diseases and HIV,”The Journal of Immunology, 2001, pp. 2420-2426, vol. 166, The American Association of Immunologists.
Davis et al., “Ligand Recognition by αβT Cell Receptors,”Annu. Rev. Immunol., 1998, pp. 523-544, vol. 16, Annual Reviews.
Ding et al., “Four A6-TCR/Peptide/HLA-A2 Structures that Generate Very Different T Cell Signals Are Nearly Identical,”Immunity, Jul. 1999, pp. 45-56, vol. 11, Cell Press.
Garcia et al., “CD8 enchances formation of stable T-cell receptor/MHC class I molecule complexes,”Nature, Dec. 12, 1996, pp. 577-581, vol. 384.
Germain et al., “The Dynamics of T Cell Receptor Signaling: Complex Orchestration and the Key Roles of Tempo and Cooperation,”Annu. Rev. Immunol., 1999, pp. 467-522, vol. 17.
Janeway, Jr., “Ligands for the T-cell receptor: hard times for avidity models,”Immunology Today, 1995, pp. 223-225, vol. 16, No. 5.
Kipriyanov et al., “Bispecific Tandem Diabody for Tumor Therapy with Improved Antigen Binding and Pharmacokinetics,”J. Mol. Biol., 1999, pp. 41-56, vol. 293, Academic Press.
Kufer et al., “Construction and biological activity of a recombinant bispecific single-chain antibody designed for therapy of minimal residual colorectal cancer,”Cancer Immunol. Immunother., 1997, pp. 193-197, vol. 45, Springer-Verlag.
Löffler et al., “A recombinant bispecific single-chain antibody, CD19 X CD3, induces rapid and high lymphoma-directed cytotoxicity by unstimulated T lymphocytes,”Blood, Mar. 15, 2000, pp. 2098-2103, vol. 95, No. 6.
Mack et al., “A small bispecific antibody construct expressed as a functional single-chain molecule with high tumor cell cytotoxicity,”Proc. Natl. Acad. Sci. USA, Jul. 1995, pp. 7021-7025, vol. 92.
Mack et al., “Biologic Properties of a Bispecific Single-Chain Antibody Directed Against 17-1A (EpCAM) and CD3,”The Journal of Immunology, 1997, pp. 3965-3970, vol. 158.
Matsui et al., “Low Affinity Interaction of Peptide-MHC Complexes with T Cell Receptors,”Science, Dec. 20, 1991, pp. 1788-1791, vol. 254.
Sykulev et al., “Kinetics and Affinity of Reactions between an Antigen-Specific T Cell Receptor and Peptide-MHC Complexes,”Immunity, Apr. 1994, pp. 15-22, vol. 1, Cell Press.
Sykulev et al., “Evidence that a Single Peptid-MHC Complex on a Target Cell Can Elicit a Cytolytic T Cell Response,”Immunity, Jun. 1996, pp. 565-571, vol. 4, Cell Press.
Vailtutti et al., “Serial triggering of many T-cell receptors by a few peptide-MHC complexes,”Nature, May 11, 1995, pp. 148-151, vol. 375.
van der Merwe et al., “Cytoskeletal polarization and redistribution of cell-surface molecules during T cell antigen recognition,”Seminars in Immunology, 2000, pp. 5-21, vol. 12.
Lanzavecchia et al., “From TCR Engagement to T Cell Activation: A Kinetic View of T Cell Behavior,”Cell, Jan. 8, 1999, pp. 1-4, vol. 96.

Affiliated with

Also associated with

Rating

Potent T cell modulating molecules does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Potent T cell modulating molecules, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Potent T cell modulating molecules will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4241648